See more What Is the Treatment for Candidemia in Nonneutropenic Patients? Recommendations
Published online: September 1, 2021
[1] It is an FDA-approved drug to treat vaginal candidiasis, oropharyngeal and
If there are vulval symptoms, consider prescribing a topical imidazole in addition to an
Detailed Fluconazole dosage information for adults and children
It is believed that higher estrogen levels and higher glycogen
Fluconazole is also used to prevent candidiasis in patients having bone marrow transplants who receive cancer or radiation treatment
Candidal vaginitis or balanitis: 150mg single dose
MONISTAT® 7 meets CDC Guidelines for treating vulvovaginal candidiasis (VVC) in pregnant women
Treatment is indicated for the relief of symptoms
Includes dosages for Vaginal Candidiasis, Oral Thrush, Onychomycosis - Toenail and more; plus renal, liver and dialysis adjustments
, blastomycosis †, candidiasis, histoplasmosis †, coccidioidomycosis †, cryptococcosis) during pregnancy
The FDA reclassified fluconazole from category C to category D (except for single 150 mg doses for vaginal candidiasis)
Miconazole nitrate 1
Monitor for potential adverse effects such as nausea, irregular uterine bleeding, breast tenderness and headache
Although it is a commonly occurring infection in up to 40% of pregnant women, it
It can be taken orally (by mouth), injected, or given by IV (into a vein)
Most commonly seen in females in high estrogen states: pregnancy, oral contraceptive use, obesity, diabetes mellitus
Spontaneous abortion between 7 and 22 weeks' gestation occurred significantly more often in women exposed to oral fluconazole than unexposed pregnancies (4
The most benign infections are characterized by local overgrowth on mucous membranes (oropharyngeal involvement, vaginitis) as a result of changes in the normal microbiota
6%) in the vaginal treatment group have used some antibiotics in the 7 weeks before the diagnosis of vulvovaginal candidiasis, whereas 5 women (14
Candidiasis occurs most commonly as a secondary infection in immunocompromised individuals